Based on these data, a phase I/II study of an anti-TLR2 antibody (OPN-305) is underway for second-line treatment of lower-risk MDS patients (Opsona Therapeutics, Dublin, Republic of Ireland). This evidence concerns the gene TLR2 and myelodysplastic syndrome.